Keveyis (U.S. rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Keveyis (U.S. rights) General Information

Description

A portfolio of U.S. rights to Keveyis drug. The asset comprises a portfolio of U.S. rights to Keveyis drug which is used for the treatment of hyperkalemia, hypokalemia, and related variants of primary periodic paralysis, which is a group of rare hereditary disorders that causes potentially severe episodes of muscle weakness and paralysis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Strongbridge Biopharma
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Keveyis (U.S. rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Keveyis (U.S. rights)‘s full profile, request access.

Request a free trial

Keveyis (U.S. rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Keveyis (U.S. rights)‘s full profile, request access.

Request a free trial

Keveyis (U.S. rights) FAQs

  • Where is Keveyis (U.S. rights) headquartered?

    Keveyis (U.S. rights) is headquartered in .

  • What industry is Keveyis (U.S. rights) in?

    Keveyis (U.S. rights)’s primary industry is Buildings and Property.

  • Is Keveyis (U.S. rights) a private or public company?

    Keveyis (U.S. rights) is a Private company.

  • What is the current valuation of Keveyis (U.S. rights)?

    The current valuation of Keveyis (U.S. rights) is .

  • What is Keveyis (U.S. rights)’s current revenue?

    The current revenue for Keveyis (U.S. rights) is .

  • Who are Keveyis (U.S. rights)’s investors?

    Taro Pharmaceutical Industries has invested in Keveyis (U.S. rights).

  • When was Keveyis (U.S. rights) acquired?

    Keveyis (U.S. rights) was acquired on 23-Dec-2016.

  • Who acquired Keveyis (U.S. rights)?

    Keveyis (U.S. rights) was acquired by Strongbridge Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process